LTRN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process...

Stats
Dagens volum	189 247
Gjennomsnittsvolum	331 506
Markedsverdi	66.17M
EPS	$0 ( 2024-03-18 )
Neste inntjeningsdato	( $-0.400 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.18
ATR14	$0.0660 (1.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-27	Fletcher Aaron G.l.	Sell	34 731	Common Stock
2024-02-28	Fletcher Aaron G.l.	Sell	51 608	Common Stock
2024-02-29	Fletcher Aaron G.l.	Sell	13 686	Common Stock
2024-02-27	Fletcher Aaron G.l.	Sell	10 620	Common Stock
2024-02-28	Fletcher Aaron G.l.	Sell	15 780	Common Stock

INSIDER POWER
-63.11
Last 98 transactions
Buy: 4 152 509 \| Sell: 1 662 260

Volum Korrelasjon

Lang: -0.13 (neutral)

Kort: -0.94 (very strong negative)

Signal:(53.547) Neutral

Lantern Pharma Inc. Korrelasjon

10 Mest positive korrelasjoner
MEUSW	0.931
CELH	0.899
CSLMU	0.895
SOUN	0.895
SUPN	0.893
NOTV	0.887
BYSI	0.884
XRTX	0.884
FSII	0.879
DGLY	0.878

10 Mest negative korrelasjoner
IOAC	-0.845
METX	-0.834
XEL	-0.83
ASRVP	-0.829
SABR	-0.826
WAVS	-0.825
CLMT	-0.81
BOWX	-0.802

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Lantern Pharma Inc. Korrelasjon - Valuta/Råvare

0.77
( moderate )

0.54
( weak )

0.00
( neutral )

0.76
( moderate )

0.37
( neutral )

-0.80
( strong negative )

Lantern Pharma Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-174 843 (0.00 %)
EPS:	$-1.470

FY	2023
Omsetning:	$0
Bruttogevinst:	$-174 843 (0.00 %)
EPS:	$-1.470

FY	2022
Omsetning:	$0
Bruttogevinst:	$-154 681 (0.00 %)
EPS:	$-1.300

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.105

Financial Reports:

No articles found.

Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Sanntidsoppdatering for Lantern Pharma Inc. [LTRN]

Upcoming Earnings Alert